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Abstract
The development of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines and 
therapeutics will depend on understanding viral immunity. We studied T cell memory in 42 
patients following recovery from COVID-19 (28 with mild disease and 14 with severe disease) and 
16 unexposed donors, using interferon-γ-based assays with peptides spanning SARS-CoV-2 
except ORF1. The breadth and magnitude of T cell responses were significantly higher in severe 
compared with mild cases. Total and spike-specific T cell responses correlated with spike-specific 
antibody responses. We identified 41 peptides containing CD4+ and/or CD8+ epitopes, including 
six immunodominant regions. Six optimized CD8+ epitopes were defined, with peptide–MHC 
pentamer-positive cells displaying the central and effector memory phenotype. In mild cases, 
higher proportions of SARS-CoV-2-specific CD8+ T cells were observed. The identification of T 
cell responses associated with milder disease will support an understanding of protective immunity 
and highlights the potential of including non-spike proteins within future COVID-19 vaccine 
design.
COVID-19 is caused by the recently emerged severe acute respiratory syndrome coronavirus 
2 (SARS-CoV-2). While the majority of COVID-19 infections are relatively mild, with 
recovery typically within 2–3 weeks[1, 2], a significant number of patients develop severe 
illness, which is postulated to be related to both an overactive immune response and viral-
induced pathology[3, 4]. The role of T cell immune responses in disease pathogenesis and 
longer-term protective immunity is currently poorly defined, but essential to understand in 
order to inform therapeutic interventions and vaccine design.
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Currently, there are many ongoing vaccine trials, but it is unknown whether they will 
provide long-lasting protective immunity. Most vaccines are designed to induce antibodies to 
the SARS-CoV-2 spike protein, but it is not yet known if this will be sufficient to induce full 
protective immunity to SARS-CoV-2 (refs. [5, 6, 7, 8]). Studying natural immunity to the 
virus, including the role of SARS-CoV-2-specific T cells, is critical to fill the current 
knowledge gaps for improved vaccine design.
For many primary virus infections, it typically takes 7-10 d to prime and expand adaptive T 
cell immune responses in order to control the virus[9]. This coincides with the typical time it 
takes for patients with COVID-19 to either recover or develop severe illness. There is an 
incubation time of 4-7 d before symptom onset and a further 7-10 d before individuals 
progress to severe disease[10]. Such a pattern of progression raises the possibility that a poor 
T cell response contributes to SARS-CoV-2 viral persistence and COVID-19 mortality, 
whereas strong T cell responses are protective in the majority of individuals.
Evidence supporting a role for T cells in COVID-19 protection and pathogenesis is currently 
incomplete and sometimes conflicting[3, 11, 12, 13, 14]. To date, there have been few 
studies analyzing SARS-CoV-2-specific T cell responses and their role in disease 
progression[15], although virus-specific T cells have been shown to be protective in human 
influenza infection[16]. In a study of CD4+ and CD8+ T cell responses to SARS-CoV-2 in 
non-hospitalized convalescent individuals, Grifoni et al.[17] found that all recovered patients 
established CD4+ responses and 70% established CD8+ memory responses to SARS-CoV-2. 
SARS-CoV-2-specific CD4+ T cell responses were also frequently observed in unexposed 
participants in their study, suggesting the possibility of pre-existing cross-reactive immune 
memory to seasonal coronaviruses. In Singapore, Le Bert et al.[18] found long-lasting T cell 
immunity to the original SARS coronavirus nucleoprotein (NP) in those who were infected 
in 2003. These T cells cross-reacted with SARS-CoV-2 NP, and T cells cross-reactive with 
non-structural proteins 7 and 13 of other coronaviruses were also present in those uninfected 
with either of the SARS coronaviruses[18].
In the present study, the overall and immunodominant SARS-CoV-2-specific memory T cell 
responses in patients who had recovered from COVID-19 were evaluated ex vivo using 
peptides spanning the full proteome of SARS-CoV-2, except ORF1. Epitopes were identified 
using two-dimensional matrix peptide pools, and CD4+ and CD8+ T cell responses were 
distinguished. The epitope specificity and human leukocyte antigen (HLA) restriction of the 
dominant CD8+ T cell responses were defined in ex vivo assays and using in vitro-cultured 
short-term T cell lines. The ex vivo functions of SARS-CoV-2-specific T cells specific for 
dominant epitopes were evaluated by their intracellular cytokine production profiles. Broad, 
and frequently strong, SARS-CoV-2-specific CD4+ and CD8+ T cell responses were seen in 
the majority of convalescent patients, with significantly larger overall T cell responses in 
those who had severe compared with mild disease. However, there was a greater proportion 
of CD8+ T cell compared with CD4+ T cell responses in mild cases, with higher frequencies 
of multi-cytokine production by matrix (M)- and NP- specific CD8+ T cells.
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A total of 42 individuals were recruited following recovery from COVID-19, including 28 
mild cases and 14 severe cases. In addition, 16 control individuals sampled in 2017–2019, 
before COVID-19 appeared, were studied in parallel. Supplementary Fig. 1 shows the 
participant characteristics. No significant differences in gender or age were noted between 
mild and severe groups. The percentage of oxyhemoglobin saturation in arterial blood 
(SaO2)/fraction of inspired O2 (FiO2) ratio in severe cases ranged from 4.3 (where 4.5 would 
be the estimate for an individual with mild disease breathing ambient air) to 1.6, with the 
patients with critical disease having an estimate of 0.8 (median in severe group = 3.8).
Ex vivo assessment of memory T cell responses specific to SARS-CoV-2
Peripheral blood mononuclear cells (PBMCs) were tested for responses to a panel of 423 
overlapping peptides spanning the SARS-CoV-2 proteome except ORF1, using ex vivo 
interferon-γ (IFN-γ) enzyme-linked immunospot (ELISpot) assays. All overlapping 
peptides were placed into two twodimensional peptide matrices. A total of 61 peptide pools 
were tested, with 29 peptides in the first-dimension pools, as described in Supplementary 
Table 1. The majority of the participants exhibited SARS-CoV-2 memory T cell responses to 
at least one of the peptides. The overall distribution, magnitude and breadth of the IFN-γ 
responses against all SARS-CoV-2 virus peptides are shown in Fig. 1. There was no 
correlation between the T cell responses and the time that had elapsed from symptom 
development (Supplementary Fig. 2). No ex vivo IFN-γ-producing SARS-CoV-2-specific T 
cell responses were observed in healthy volunteers, who were all sampled before any chance 
of exposure, but in those with appropriate HLA types, T cell responses were observed to 
influenza virus, Epstein–Barr virus and cytomegalovirus (CMV) using pools of known T cell 
epitopes, as well as phytohemagglutinin, as positive controls (Supplementary Fig. 3). The 
breadth and magnitude of the T cell responses varied considerably between individuals. T 
cell responses were detected against epitopes distributed across a wide variety of virus 
proteins. Significantly higher-magnitude (P = 0.002) and broader (P = 0.002) overall T cell 
responses were observed in severe cases compared with mild cases, in particular for 
responses to spike (P = 0.021 for magnitude; P = 0.016 for breadth), membrane (P = 0.0003 
for magnitude; P = 0.033 for breadth), ORF3 (P < 0.0001 for magnitude; P < 0.001 for 
breadth) and ORF8 proteins (P = 0.011 for magnitude; P = 0.014 for breadth) (Fig. 2). 
Overall, we found that strong and broad T cell memory responses were induced after 
recovery from COVID-19, and the breadth and magnitude of T cell responses were 
significantly higher in severe compared with mild cases.
Correlation with spike-specific antibody responses
The relationships between overall and spike-specific T cell responses and spike-specific, 
receptor-binding domain (RBD)-specific and NP-specific antibody end-point titers (EPTs) 
were assessed (Fig. 3 and supplementary figure 4). There were significant correlations 
between: (1) spike-specific antibody titers and both overall T cell responses (P = 0.0004; R = 
0.5185) and spike-specific T cell responses (P = 0.0006; R = 0.505); (2) RBD-specific 
antibody titers and both overall T cell responses (P = 0.0004; R = 0.5198) and spike-specific 
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T cell responses (P = 0.0004; R = 0.5189); and (3) NP-specific antibody titers and both 
overall T cell responses (P = 0.0015; R = 0.4738) and spike-specific T cell responses (P = 
0.007; R = 0.412). However, there was no significant association between NP-specific 
antibody titers and NP-specific T cell responses (P = 0.067; R = 0.286) (Supplementary Fig. 
4). Moreover, significantly higher levels of spike, RBD and NP EPTs were observed in 
severe cases compared with mild cases (Fig. 3d). It was noted that some individuals had low 
RBD-specific antibodies (Fig. 3b), yet had detectable spike-specific antibodies (Fig. 3a), 
suggesting that antibodies were able to target non-RBD regions of spike. This is under 
further investigation. Thus, total and spike-specific T cell responses were found to be 
correlated with spike-specific antibody responses.
Distribution of SARS-CoV-2-specific CD4+ and CD8+ memory T cell responses
Having identified overall T cell responses to SARS-CoV-2 peptides, the responses detected 
against positive peptide pools were characterized by flow cytometry for peptide recognition 
by CD4+ or CD8+ T cell subsets and for intracellular production of IFN-γ, tumor necrosis 
factor-α (TNF-α) and interleukin-2 (IL-2) after stimulation (Fig. 4a,b and Supplementary 
Fig. 5). A greater proportion of the T cell responses to spike (P = 0.0268) and M/NP (P = 
0.02) were contributed to by CD8+ T cells in those with mild disease compared with those 
with severe disease (Fig. 4c and Supplementary Fig. 6a). Differential subsets of SARS-
CoV-2-specific T cells therefore associate with clinical outcome.
Evaluation of the polyfunctionality of T cells responding to SARS-CoV-2 peptides
Multi-cytokine analysis revealed patterns of IFN-γ, TNF and IL-2 production by CD4+ and 
CD8+ T cells in both mild and severe cases (Fig. 5a). For 22 individuals tested, both CD4+ 
and CD8+ antigen-specific T cells produced at least one of these three cytokines and others 
in combination. CD8+ but not CD4+ T cells targeting different virus proteins showed 
different cytokine profiles, with the M/NP-specific CD8+ T cells showing wider 
functionality than T cells targeting spike protein (P = 0.0231; Fig. 5b and Supplementary 
Fig. 6b). Furthermore, there were a greater proportion of multifunctional M/NP-specific 
CD8+ T cells compared with spike-specific T cells in those who had mild disease (P = 
0.0037), but not in those who had severe disease (P = 0.3823). In contrast with observations 
seen in influenza virus infection[19], we did not observe significant differences in the 
cytotoxic potential (as indicated by expression of the degranulation marker CD107a) in 
patients with mild and severe disease (Fig. 5c) and we observed very few CD107a+CD4+ T 
cells overall, suggesting that cytotoxic CD4+ T cells might not be a major contributor to 
virus clearance.
Identification of SARS-CoV-2-specific T cell peptides containing epitopes
IFN-γ ELISpot assays were performed with candidate peptides identified from the two-
dimensional matrix analysis in 34 participants. A total of 41 peptides containing SARS-
CoV-2 T cell epitope regions were recognized by convalescent individuals who had 
COVID-19: 18 from spike, ten from NP, six from membrane and seven from ORF proteins. 
Strikingly, six dominant 18-mer peptides were recognized by six or more of the 34 
participants tested (Table 1). NP-16 was recognized by 12 out of 34 (35%) participants 
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tested and contained at least two epitopes that were recognized by either CD4+ T or CD8+ T 
cells.
M-24 was recognized by 16 out of 34 participants (47%) tested and contained one or more 
CD4+ T cell epitopes. Peptide M-20 was recognized by 11 out of 34 participants tested 
(32%) and contained one or more CD4+ T cell epitopes. Three dominant spike peptides were 
also identified, with S-34 recognized by ten out of 34 participants (29%) containing both 
CD4+ and CD8+ T cell epitopes, and a further two spike peptides (S-151 and S-174) were 
recognized by eight and six out of 34 participants, respectively (24 and 18%), both 
containing CD4+ T cell epitopes.
Those dominant responses were further confirmed by ex vivo assays and using cultured 
short-term T cell lines. Supplementary Fig. 7 illustrates examples of fluorescence-activated 
cell sorting plots from intracellular cytokine staining (ICS) when short-term T cell lines 
were stimulated with single peptides containing epitopes. CD4+ T cells elicited strong 
responses against dominant spike peptides and M peptides, whereas cells targeting two NP-
dominant peptides were CD8+ T cells. The optimum epitopes within the long peptides 
recognized by dominant CD8+ T cells, and their HLA restriction matched to the donor’s 
HLA type, were predicted using the Immune Epitope Database analysis resource (http://
tools.iedb.org/mhci). The best-predicted epitope sequences are shown in Supplementary 
Table 2.
A set of previously defined SARS epitopes[20] with identical sequences to SARS-CoV-2 
were also tested by ELISpot assay (Supplementary Table 3). Most of those peptides did not 
elicit any positive responses in 42 individuals who had recovered from COVID-19, apart 
from two NP epitope peptides (N-E-3 (MEVTPSGTWL) and N-E-11 
(LLNKHIDAYKTFPPTEPK)) and one spike epitope peptide (S-E-19; 
QLIRAAEIRASANLAATK). N-E-11, which is identical to peptide NP-51, shares the 
sequence with two other known HLA-A*0201-restricted SARS epitopes (N-E-1 
(ILLNKHID) and N-E-5 (ILLNKHIDA)). Interestingly, one of the responders to this peptide 
did not carry the HLA-A*0201 allele (Table 1), indicating that this peptide may contain a 
different SARS-CoV-2 epitope presented by a different HLA molecule. Whereas these NP 
epitopes are targeted by CD8+ T cells, we also detected a CD4+ T cell response targeting 
SARS spike epitope S-E-19, which spans between the overlapping peptides of S-203 and 
S-204. This peptide is known to be presented by HLA-DRB1*0401 in SARS infection.
The optimum peptide sequences and their HLA restrictions were confirmed by generating 
short-term T cell lines and clones, which were tested in ELISpot assays by co-culturing with 
peptide-loaded HLA-matched and -unmatched immortalized B lymphoblastoid cell lines, as 
previously described[21]. In total, six CD8+ T cell epitopes restricted by HLA-A*0101, -
A*0301, -A*1101, -B*0702, -B*4001 and -B*2705 were confirmed (Table 2). HLA-peptide 
pentamers were synthesized comprising five peptides bound to the appropriate HLA class I 
molecules. T cell staining was verified by flow cytometry (Fig. 6) and their phenotypes were 
determined (Fig. 7). A pentameric HLA-A*0201 with the spike epitope reported by 
Shomuradova et al.[22], was synthesized. Only one out of six HLA-A*0201-positive donors 
showed detectable staining, but at a very low frequency. The majority of pentamer-stained 
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SARS-CoV-2-specific CD8+ T cells exhibited central memory (20.7 ± 8.4%) or effector 
memory phenotypes (50.3 ± 13.3%) (Fig. 7) and early (CD27+CD28+; 43.8 ± 20.9%) or 
intermediate (CD27+CD28-; 49.3 ± 21.0%) differentiation phenotypes. Overall, multiple 
peptides containing epitopes and immunodominant regions were defined from 42 individuals 
who had recovered from COVID-19. The regions were located in the majority of SARS-
CoV-2 structural and non-structural proteins, including spike, M, NP and ORF proteins, with 
CD8+ T cells exhibiting central memory and effector memory phenotypes.
Discussion
This study demonstrates the presence of robust memory T cell responses specific for SARS-
CoV-2 in the blood of donors who have recovered from COVID-19. The broader and 
stronger SARS-CoV-2-specific T cell responses in patients who had severe disease may be 
the result of higher viral loads and may reflect a poorly functioning early T cell response 
that failed to control the virus, in addition to other factors such as direct virus-induced 
pathology associated with larger viral inoculums or poorer innate immunity. Alternatively, it 
is possible that the T cell response was itself harmful and contributes to disease severity. 
Consistent with recent reports from Grifoni et al.[17] and Sekine et al. [23], a particularly 
high frequency of spike protein-specific CD4+ T cell responses was observed in patients 
who had recovered from COVID-19. This is very similar to influenza virus infection, where 
viral surface hemagglutinin elicited mostly CD4+ T cell responses, whereas the majority of 
CD8+ T cell responses were specific to viral internal proteins[24]. Understanding the roles 
of different subsets of T cells in protection or pathogenesis is crucial for the prevention and 
treatment of COVID-19. The timing and strength of the first T cell responses could be 
critical in determining this balance at an early stage of the infection.
Among the 41 peptides containing T cell epitopes that were identified in this study, six 
immunodominant epitope groups (peptides) were frequently targeted by T cells in many 
donors, including three in spike protein (29, 24 and 18%), two in membrane protein (32 and 
47%) and one in NP (35%). The immunodominant peptide regions identified here may 
include multiple epitopes restricted by different HLAs (both class I and II, such as S-34 and 
NP-16), with immunodominance preferences imposed by the antigen-processing pathways. 
Whether or not these dominant responses play a role in immune protection merits further 
investigation in larger prospective cohorts.
A higher proportion of CD8+ T cell responses was observed in mild disease, suggesting a 
potential protective role of CD8+ T cell responses in mild disease or a pathogenic role of 
CD4+ T cell responses in severe disease, which merits further investigation.
The majority of pentamer-binding CD8+ T cells were effector memory and central memory 
with early and intermediate differentiation phenotypes, with functional potential on antigen 
re-exposure. Because the number of donors studied was limited and they would probably 
show diverse T cell receptors, peptide–major histocompatibility complex (MHC) affinities 
and antigen sensitivities for the different epitopes, it was not possible to make a detailed 
analysis comparing mild and severe cases. However, the groundwork, including epitope 
identification, was laid for future studies that can address this important issue.
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Multiple strong dominant T cell responses were seen in study participants that were specific 
for the M and NP proteins. Dominant epitope regions within NP (NP-16) were detected in 
35% of study participants, and dominant epitope regions within matrix (M-20 and M-24) 
were detected in 32 and 47%, respectively. In addition, a higher proportion of multi-
cytokine-producing M/NP-specific T cells compared with spike-specific CD8+ T cells were 
observed in individuals who had recovered from mild disease. A similar trend was also 
observed in severe cases, although this was not significant, possibly due to fewer cases. 
These data strongly suggest that NP and M have the potential for inclusion within future 
vaccines so as to stimulate strong effector T cell responses. Furthermore, T cells responding 
to these antigens may be more cross-reactive[18].
IFN-γ-producing SARS-CoV-2-specific T cell responses were not observed in 16 healthy 
unexposed volunteers, in contrast with recently published reports by Grifoni et al.[17] and 
Braun et al.[25], both of which used peptide-stimulated activation-induced marker (AIM) 
assays. In contrast, in a recent immunogenicity study of a recombinant adenovirus type-5-
vectored COVID-19 vaccine human phase I trial in 108 volunteers without pre-exposure to 
COVID-19, spike-specific T cell responses, measured IFN-γ ELISpots and ICS assays were 
not found before vaccination[6]. These differences could result from differences in the 
sensitivity of the detection methods.
AIM versus IFN-γ production assays
IFN-γ ELISpot and ICS are well-established methods for evaluating antigen-specific T cells, 
used in different virus infections and vaccine studies, that have direct functional 
relevance[24, 26, 27, 28]. The AIM assay is a more recently developed assay, capable of 
detecting early-responding T cells, that is independent of cytokine production. Both methods 
are valid but differ in sensitivity and possible functional relevance. However, it is also 
possible that different circulating coronaviruses have been previously present in the different 
geographical populations studied, giving cross-reactive responses in some regions but not 
others, as suggested by Le Bert et al.[18]. These T cell cross-reacting viruses could include 
not only SARS-CoV-1 and human common cold coronaviruses, but also other unknown 
coronaviruses of animal origin. It is also known that very sensitive assays can detect not only 
pre-existing naive antigen-specific CD4+ T cells but also memory CD4+ T cells. The latter 
are potentially primed by other microbes that cross-react with viruses as diverse as CMV, 
human immunodeficiency virus type 1 and Ebola virus in most unexposed humans[29, 30]. 
Therefore, similar findings with SARS-CoV-2 peptides do not necessarily mean the T cells 
were primed by previous infecting coronaviruses. Indeed, the implications of pre-existing 
cross-reactivity to seasonal coronavirus and other viruses for COVID-19 immunity merit 
further detailed investigation, as highlighted by Sette and Crotty[31].
This study focuses on T cell responses in PBMCs. There remains a lack of understanding of 
memory T cells at the site of infection, which probably provide the most potent protection, 
as observed in influenza virus infection[32]. It is possible that the hierarchy of 
immunodominant circulating blood memory T cell pools may not exactly reflect that of 
memory T cells in the lungs[17, 33, 34]. Therefore, understanding the features of tissue-
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resident memory T cells and their association with disease severity will be critical and also 
merits further investigation.
Taken together, this study has demonstrated strong and broad SARS-CoV-2-specific CD4+ 
and CD8+ T cell responses in the majority of humans who had recovered from COVID-19. 
The immunodominant epitope regions and peptides containing T cell epitopes identified in 
this study will provide critical tools with which to study the contribution of SARS-CoV-19-
specific T cells in protection and immune pathology. The identification of non-spike 
dominant CD8+ T cell epitopes suggests the potential importance of including non-spike 
proteins such as NP, M and ORFs in future vaccine designs.
Methods
Ethics
Patients were recruited from the John Radcliffe Hospital in Oxford, United Kingdom, 
between March and May 2020 by the identification of patients hospitalized during the 
SARS-COV-2 pandemic and recruited into the Sepsis Immunomics and International Severe 
Acute Respiratory and Emerging Infection Consortium World Health Organization Clinical 
Characterisation Protocol UK (IRAS260007 and IRAS126600). Patients were sampled at 
least 28 d from the start of their symptoms. Unexposed healthy adult donor samples were 
used from unrelated studies undertaken between 2017 and early 2019. Written informed 
consent was obtained from all patients. Ethical approval was given by the South Central–
Oxford C Research Ethics Committee in England (reference: 13/SC/0149), Scotland A 
Research Ethics Committee (reference: 20/SS/0028) and World Health Organization Ethics 
Review Committee (RPC571 and RPC572l; 25 April 2013).
Clinical definitions
All patients were confirmed to have a test positive for SARS-CoV-2 using PCR with reverse 
transcription from an upper respiratory tract (nose and throat) swab tested at an accredited 
laboratory. The degree of severity was identified as mild, severe or critical infection, 
according to recommendations from the World Health Organization. Patients were classified 
as having mild symptoms if they did not require oxygen (that is, their oxygen saturation was 
greater than 93% on ambient air) or if their symptoms were managed at home. A large 
proportion of our mild cases were admitted to hospital for public health reasons during the 
early phase of the pandemic even though they had no medical reason to be admitted to 
hospital. Severe infection was defined as one of the following conditions in a patient 
confirmed as having COVID-19: respiratory distress with a respiratory rate of >30 breaths 
per minute; blood oxygen saturation of <93%; or arterial oxygen partial pressure/FiO2 < 300 
mmHg. Critical infection was defined as: respiratory failure requiring mechanical ventilation 
or shock; or other organ failures requiring admission to an intensive care unit. Since the 
severe classification could potentially include individuals spanning a wide spectrum of 
disease severity, ranging from patients receiving oxygen through a nasal cannula through to 
those receiving non-invasive ventilation, we also calculated the SaO2/FiO2 ratio at the height 
of patient illness as a quantitative marker of lung damage. This was calculated by dividing 
the oxygen saturation (as determined using a bedside pulse oximeter) by the fraction of 
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inspired oxygen (21% for ambient air; 24% for nasal cannulae; 28% for simple face masks; 
28, 35, 40 or 60% for Venturi face masks; or precise measurements for non-invasive or 
invasive ventilation settings). Patients not requiring oxygen who had oxygen saturations (if 
measured) greater than 93% on ambient air or managed at home were classified as having 
mild disease. Viral swab Ct values were not available for all patients. In addition, we 
standardized all of our analyses to the days since symptom onset.
Synthetic peptides
A total of 423 15- to 18-mer peptides overlapping by ten amino acid residues and spanning 
the full proteome of SARS-CoV-2 except ORF1 (Supplementary Table 1) were designed 
using the software PeptGen (http://www.hiv.lanl.gov/content/sequence/PEPTGEN/
peptgen.html) and synthesized (purity: >75%; ProImmune).
A total of 27 previously defined SARS epitopes[20] were also synthesized (Supplementary 
Table 2). Pools of CMV, Epstein-Barr virus and influenza virus-specific epitope peptides and 
the human immunodeficiency virus Gag protein were also used as positive and negative 
controls.
Two-dimensional peptide matrix system
The overlapping peptides spanning SARS-CoV-2 were assigned to a two-dimensional matrix 
system in which each peptide was represented in two different peptide pools. Each peptide 
pool contained no more than 16 individual peptides. The first dimension of the peptide 
matrix system was designed so that peptides from different source proteins were separated 
into different pools. (Supplementary Table 1).
Ex vivo ELISpot assay
IFN-γ ELISpot assays were performed using either freshly isolated or cryopreserved 
PBMCs, as described previously. No significant difference was observed between responses 
generated by fresh and cryopreserved PBMCs, as described previously[24, 35].
Overlapping peptides were pooled and then added to 200,000 PBMCs per test at a final 
concentration of 2 μg ml-1 for 16-18 h. The positive responses were confirmed by repeat 
ELISpot assays. To quantify antigen-specific responses, mean spots of the control wells 
were subtracted from the positive wells, and the results were expressed as spot-forming units 
(s.f.u.) per 106 PBMCs. Responses were considered positive if the results were at least three 
times the mean of the negative control wells and >25 s.f.u. per 106 PBMCs. If negative 
control wells had >30 s.f.u. per 106 PBMCs or positive control wells (phytohemagglutinin 
stimulation) were negative, the results were excluded from further analysis.
Determination of plasma binding to trimeric spike, RBD and NP by enzyme-linked 
immunosorbent assay
MaxiSorp immunoplates (442404; NUNC) were coated with 0.125 μg StrepMAB-Classic 
(2-1507-001; IBA), blocked with 2% skimmed milk in phosphate-buffered saline (PBS) for 
1 h and then incubated with 50 μl of 5 μg ml-1 soluble trimeric spike and 2 μg ml-1 of 2% 
skimmed milk in PBS. After 1 h, 50 μl of serial twofold dilutions of plasma, from 1:50 to 
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1:51,200 in PBS containing 2% skimmed milk, were added followed by Alkaline 
phosphatase-conjugated anti-human IgG (A9544; Sigma-Aldrich) at 1:10,000 dilution. The 
reaction was developed by the addition of para-nitrophenyl phosphate substrate and stopped 
with NaOH. The absorbance was measured at 405 nm. EPTs were defined as reciprocal 
plasma dilutions that corresponded to two times the average optical density values obtained 
with mock. To determine EPTs to RBD and NP, immunoplates were coated with 0.125 μg 
Tetra-His antibody (34670; Qiagen) followed by 2 and 5 μg ml-1 of soluble RBD and NP, 
respectively.
ICS
ICS was performed as described previously[36, 37]. Briefly, overnight-rested PBMCs were 
stimulated with pooled or individual peptides at a final concentration of 10 μg ml-1 for 1 h in 
the presence of 2 μg ml-1 monoclonal antibodies CD28 and CD49d, and then for an 
additional 5 h with GolgiPlug, GolgiStop, and surface stained with PE-anti-CD107a. Dead 
cells were labeled using LIVE/DEAD Fixable Aqua dye from Invitrogen. Surface markers, 
including BUV395-anti-CD3, BUV737-anti-CD4, PerCP-Cy5.5-anti-CD8, BV510-anti-
CD14, BV510-anti-CD16 and BV510-anti-CD19 (BioLegend) were stained. Cells were then 
washed, fixed with Cytofix/Cytoperm and stained with PE-Cy7-anti-IFNγ (eBioscience), 
APC-anti-TNFα (eBioscience) or BV421-anti-IL-2 (BioLegend). Negative controls without 
peptide stimulation were run for each sample. All reagents were from BD Biosciences 
unless otherwise stated. All samples were acquired on a BD LSRFortessa (BD Biosciences) 
flow cytometer and analyzed using FlowJo version 10 software. Peptide pool-reactive CD4+ 
or CD8+ T cells with a frequency lower than 0.05% of CD4+ or CD8+ T cells, respectively, 
were excluded from analysis. Cytokine responses were background subtracted individually 
before further analysis. To determine the frequency of different response patterns based on 
all possible combinations, Boolean gates were created using IFN-γ, TNF-α and IL-2. 
Cytokine responses were background subtracted individually before further analysis.
Pentamer phenotyping
Cryopreserved PBMCs were thawed, as described above. A total of 1 × 106 live PBMCs 
were labeled with peptide-MHC class I Pentamer-PE (ProImmune) and incubated for 15 min 
at 37 °C. Dead cells were first labeled with LIVE/DEAD Fixable Aqua dye (Invitrogen) and 
then with the surface markers CD3-BUV395, CD8-PerCP.Cy5.5, CD14-BV510, CD16-
BV510, CD19-BV510, CD28-BV711, CD27-APC-R700, CD45RA-APC-H7 and CCR7-PE-
Dazzel 594 (BioLegend). All reagents were from BD Biosciences unless otherwise stated. 
All samples were acquired on a BD LSRFortessa (BD Biosciences) flow cytometer and 
analyzed using FlowJo version 10 software.
Generation of short-term T cell lines
Short-term SARS-CoV-2-specific T cell lines were established as previously described[35]. 
Briefly, 3 × 106 to 5 × 106 PBMCs were pulsed as a pellet for 1 h at 37 °C with 10 μM of 
peptides containing T cell epitope regions and cultured in R10 at 2 × 106 cells per well in a 
24-well Costar plate. IL-2 was added to a final concentration of 100 U ml-1 on day 3 and 
cultured for further 10-14 d.
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Statistical analysis was performed with IBM SPSS Statistics 25 and the figures were made 
with GraphPad Prism 8. Chi-squared tests were used to compare ratio differences between 
two groups. After testing for normality using the Kolmogorov–Smirnov test, the 
independent-samples t-test or Mann–Whitney U- test was employed to compare variables 
between two groups. Correlations were performed via Spearman’s rank correlation. 
Statistical significance was set at *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001. 
All of the tests were two tailed.
Reporting Summary
Further information on research design is available in the Nature Research Reporting 
Summary linked to this article.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Questions have arisen as to whether patients with severe COVID-19 disease can generate 
a T cell response against SARS-CoV-2. Tao Dong and colleagues report that convalescent 
patients with COVID-19 harbor functional memory CD4+ and CD8+ T cells that 
recognize multiple epitopes that span the viral proteome. CD4+ T cells predominated the 
memory response in patients with severe disease, whereas higher proportions of CD8+ T 
cells were found in patients with mild disease.
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Fig. 1. Memory T cell responses specific to SARS-CoV-2 virus proteins in 42 convalescent 
patients infected with SARS-CoV-2.
Of the 42 patients studied, 28 had mild symptoms while 14 showed severe symptoms. 
PBMCs were isolated and IFN-γ production was detected by ELISpot after incubation with 
SARS-CoV-2 peptides. a, Magnitude of IFN-γ T cell responses for each individual. Each 
bar shows the total T cell responses of each individual specific to all of the SARS-CoV-2 
protein peptides tested. Each colored segment represents the source protein corresponding to 
peptide pools eliciting IFN-γ T cell responses. b, Breadth of T cell responses for each 
individual. The breadth of T cell responses was calculated by the number of peptide pools in 
the first-dimension (n = 29) cells that responded to spot-forming units. The experiments 
were repeated in 35 participants where sample availability permitted. Env: envelope protein
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Fig. 2. Comparison of the magnitude and breadth of T cell responses specific to each viral 
protein between convalescent patients with mild symptoms and those with severe symptoms.
PBMCs were isolated and IFN-γ production was detected by ELISpot after incubation with 
SARS-CoV-2 peptides. a,b, Magnitude (a) and breadth (b) of T cell responses against each 
viral protein between those with mild symptoms (n = 28) and those with severe symptoms 
(n= 14). P values were as follows: overall: P = 0.002 for magnitude; P = 0.002 for breadth; 
spike: P = 0.021 for magnitude; P = 0.016 for breadth; membrane: P = 0.0003 for 
magnitude; P = 0.033 for breadth; ORF3a: P < 0.0001 for magnitude; P = 0.001 for breadth; 
ORF8: P = 0.011 for magnitude; P = 0.014 for breadth. Data are presented as medians with 
interquartile ranges. The Mann–Whitney U-test was used for the analysis and two-tailed P 
values were calculated. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.001. NS, not 
significant.
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Fig. 3. Correlation of T cell responses against SARS-CoV-2 with spike-, RBD- and NP-specific 
antibody responses.
a-c, Spike (a), RBD (b) and NP EPTs (c) in association with overall T cell responses. Red 
and black data points represent patients with severe and mild symptoms, respectively. n = 
42. Spearman’s rank correlation coefficients (R) are shown. d, Comparison of spike EPTs (P 
< 0.0001), RBD EPTs (P < 0.0001) and NP EPTs (P = 0.0004) for patients with mild 
symptoms (n = 28) versus severe symptoms (n = 14). Data are presented as medians with 
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interquartile ranges and a Mann-Whitney U-test was used for comparison. Two-tailed P 
values were calculated. ***P < 0.001; ****P < 0.0001.
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Fig. 4. Distribution of SARS-CoV-2-specific CD4+ and CD8+ memory T cell responses.
Cytokine-producing T cells were detected by ICS after incubation with SARS-CoV-2 
peptides. a,b, Flow cytometric plots representing CD4+ T cells (a) and CD8+ T cells (b) 
expressing IFN-γ (x axis), TNF (y axis) and/or IL-2 (y axis) upon stimulation with the 
respective SARS-CoV-2 peptide pools in examples of mild (left) and severe cases (right). c, 
Comparison of the relative proportion of SARS-CoV-2 peptide pool-reactive CD8+ T cells 
between mild (spike, n = 11; M/NP, n = 14; ORF/Env, n = 5; overall: n = 14) and severe 
cases (spike, n = 7; M/NP, n = 7; ORF/Env, n = 4; overall, n = 8). P values were as follows: P 
= 0.0268 (spike); P = 0.02 (M/NP); P = 0.0159 (overall). The SARS-CoV-2 peptide pool-
reactive CD4+ or CD8+ T cells were identified with at least one of the three cytokines (IFN-
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γ, TNF and IL-2) detected. Data are shown as medians with interquartile ranges. The Mann-
Whitney U-test was used for the analysis. Two-tailed P values were calculated. *P < 0.05.
Peng et al. Page 25









































Fig. 5. Cytokine profile of SARS-Cov-2-specific T cells.
The cytokine production of SARS-Cov-2-specific T cells was assessed by ICS after 
incubation with SARS-CoV-2 peptides. a, Pie charts representing the relative proportions of 
spike-, M/NP- and ORF/env-specific CD4+ and CD8+ T cells producing one (green), two 
(pink) or three cytokines (black) (out of IFN-γ, TNF and IL-2). b, Comparison of the 
frequency of multifunctional CD8+ T cells targeting spike and M/NP. The open circles and 
squares represent T cell responses in mild cases and severe cases, respectively. P values are 
as follows: P = 0.0037 (mild); P = 0.3823 (severe); P = 0.0231 (overall). c, Relative 
frequencies of CD4+ and CD8+ T cells expressing CD107a after antigen stimulation. The 
data shown are from 14 patients with mild symptoms and eight patients with severe 
symptoms. The Mann–Whitney U-test was used for the analysis. Two-tailed P values were 
calculated. *P < 0.05; **P < 0.01.
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Fig. 6. Defined SARS-CoV-2-specific CD8 epitopes.
Examples of peptide–MHC class I pentamer staining ex vivo, with PBMCs (HLA-B*0702, -
B*4001, -A*1101, -A*0101 and -A*0201) or with cultured cell lines (HLA-A*0301). 
Eleven donors were tested with positive pentamer staining.
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Fig. 7. Memory phenotype and differentiation status of SARS-CoV-2-specific CD8+ T cells.
PBMCs were isolated and stained with peptide–MHC class I pentameric complexes and 
markers of T cell memory and differentiation. a, Representative fluorescence-activated cell 
sorting plots of gating for different cell subsets. b,c, Expression of memory markers (CCR7 
and CD45RA) (b) and differentiation markers (CD27 and CD28) (c) on CD8+ pentamer+ T 
cells. n = 7 donors. Data are presented as means ± s.e.m.
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Table 1
Peptides containing T cell epitopes
Peptide Position Amino acid sequence CD4+/CD8+ T cell response Number of participants
Spike(n = 18)
S-34
a 166-180 CTFEYVSQPFLMDLE 4/8 10
S-39 191-205 EFVFKNIDGYFKIYS NA 1
S-42 206-230 KHTPINLVRDLPQGF NA 1
S-43 211-225 NLVRDLPQGFSALEP NA 1
S-71 351-365 YAWNRKRISNCVADY 4 1
S-77 381-395 GVSPTKLNDLCFTNV 4 1
S-90 446-460 GGNYNYLYRLFRKSN NA 1
S-91 451-465 YLYRLFRKSNLKPFE NA 1
S-103 506-520 VVLSFELLHAPATVC 4 1
S-106 526-540 GPKKSTNLVKNKCVN 8 1
S-145 721-735 SVTTEILPVSMTKTS NA 1
S-150 746-760 STECSNLLLQYGSFC NA 1
S-151
a 751-765 NLLLQYGSFCTQLNR 4 8
S-161 801-815 NFSQILPDPSKPSKR 4 2
S-174
a 866-880 TDEMIAQYTSALLAG 4 6
S-235 1,171-1,185 GINASVVNIQKEIDR NA 1
S-240 1,196-1,210 LIDLQELGKYEQYI NA 1
S-242 1,206-1,220 YEQYIKWPWYIWLGF NA 1
NP (n =10)
NP-1 1-17 MSDNGPQNQRNAPRITF 8 3
NP-2 8-25 NQRNAPRITFGGPSDSTG 8 3
NP-12 82-95 DQIGYYRRATRRIR NA 1
NP-15 101-113 MKDLSPRWYFYYL NA 1
NP-16
a 104-121 LSPRWYFYYLGTGPEAGL 4/8 12
NP-46 313-330 AFFGMSRIGMEVTPSGTW NA 1
NP-47 321-338 GMEVTPSGTWLTYTGAIK NA 1
NP-48 329-346 TWLTYTGAIKLDDKDPNF 4 2
NP-50 344-361 PNFKDQVILLNKHIDAYK 4 1
NP-51 352-369 LLNKHIDAYKTFPPTEPK 8 3
M19 133-150 LLESELVIGAVILRGHLR NA 3
M (n= 6)
M-20
a 141-158 GAVILRGHLRIAGHHLGR 4 11
M-21 149-166 LRIAGHHLGRCDIKDLPK NA 3
M-23 165-181 PKEITVATSRTLSYYKL NA 3
M-24
a 172-188 TSRTLSYYKLGASQRVA 4 16
M-28 201-218 IGNYKLNTDHSSSSDNIA NA 1
ORFs(n =7) ORF3a-20 145-160 YFLCWHTNCYDYCIPY NA 1
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Peptide Position Amino acid sequence CD4+/CD8+ T cell response Number of participants
ORF3a-27 198-215 KDCVVLHSYFTSDYYQLY NA 3
ORF3a-28 206-225 YFTSDYYQLYSTQLSTDTGV 8 4
ORF3a-30 224-243 GVEHVTFFIYNKIVDEPEEH NA 1
ORF7a-2 9-25 LITLATCELYHYQECVR NA 3
ORF7a-7 46-63 FHPLADNKFALTCFSTQF NA 1
ORF7a-10 69-86 DGVKHVYQLRARSVSPKL 4 1
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Table 2
Location, sequence and HLA restriction of six identified SARS-CoV2 CD8 optimum 
epitopes







ORF3a 207-215 FTSDYYQLY A*0101
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